Posted by Michael Wonder on 23 Nov 2023
AnHeart Therapeutics and Innovent announce China’s NMPA has accepted a new drug application for taletrectinib (ROS1 inhibitor)
22 November 2023 - AnHeart Therapeutics and Innovent Biologics today announced that the Center for Drug Evaluation of China’s NMPA has accepted a new drug application for taletrectinib, a next generation ROS1 tyrosine kinase inhibitor, for adult patients with locally advanced or metastatic ROS1 positive non-small cell lung cancer who have been previously treated with ROS1 tyrosine kinase inhibitors.
